Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Hae Il Jung, Dongjun Jeong, Sanghee Ji, Tae Sung Ahn, Sang Ho Bae, Susie Chin, Jun Chul Chung, Hyung Chul Kim, Moon Soo Lee, Moo-Jun Baek
Cancer Res Treat. 2017;49(1):246-254.   Published online 2016 Jul 7     DOI: https://doi.org/10.4143/crt.2016.066
Citations to this article as recorded by Crossref logo
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers
Guoying Zhou, Patrick P. C. Boor, Marco J. Bruno, Dave Sprengers, Jaap Kwekkeboom
British Journal of Cancer.2022; 126(1): 10.     CrossRef
Synergistic antitumor efficacy of PD-1-conjugated PTX- and ZSQ-loaded nanoliposomes against multidrug-resistant liver cancers
Mingjia Gu, Fang Yin, Yuening Qin, Yali Tian, Xinjie Xiu, Hanjing Shen, Jiebin Zhu
Drug Delivery and Translational Research.2022; 12(10): 2550.     CrossRef
Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
Uasim Harkus, Miriam Wankell, Pranavan Palamuthusingam, Craig McFarlane, Lionel Hebbard
Seminars in Cancer Biology.2022; 86: 799.     CrossRef
Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis
Ramy R. Saleh, Jordan L. Scott, Nicholas Meti, Danielle Perlon, Rouhi Fazelzad, Alberto Ocana, Eitan Amir
Molecular Diagnosis & Therapy.2022; 26(2): 153.     CrossRef
Identification of Potential Immune Checkpoint Inhibitor Targets in Gliomas via Bioinformatic Analyses
Mengmeng Ding, Yong-an Li, Zhimin Lu, Guoxin Hou, Aziz ur Rehman Aziz
BioMed Research International.2022; 2022: 1.     CrossRef
LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1
Zhijia Sun, Chunyuan Xue, Jiangbo Li, Hui Zhao, Yimeng Du, Nan Du
Bioengineered.2022; 13(3): 7635.     CrossRef
Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma
Mahsa Pourhamzeh, Samieh Asadian, Hamed Mirzaei, Azita Minaei, Elahe Shahriari, Anastasia Shpichka, Hamidreza Aboulkheyr Es, Peter Timashev, Moustapha Hassan, Massoud Vosough
Molecular and Cellular Biochemistry.2022;[Epub]     CrossRef
Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach
Eslam E. Abd El-Fattah, Amr Y. Zakaria
International Immunopharmacology.2022; 109: 108889.     CrossRef
Association of Increased Programmed Death Ligand 1 Expression and Regulatory T Cells Infiltration with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection
Long-Bin Jeng, Tsai-Chung Li, Shih-Chao Hsu, Chiao-Fang Teng
Viruses.2022; 14(6): 1346.     CrossRef
Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma
Baifeng Qian, Haozhong Lin, Tian Lan, Muqi Li, Xiwen Wu, Shuirong Lin, Zimin Song, Shunli Shen, Baogang Peng
World Journal of Surgical Oncology.2022;[Epub]     CrossRef
Pilot Study: Immune Checkpoints Polymorphisms in Greek Primary Breast Cancer Patients
Nyanbol Kuol, Xu Yan, Vanessa Barriga, Jimsheena Karakkat, Stamatis Vassilaros, Ioannis Fyssas, Anastasios Tsimpanis, Sarah Fraser, Kulmira Nurgali, Vasso Apostolopoulos
Biomedicines.2022; 10(8): 1827.     CrossRef
Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma
Shengkui Tan, Xuefeng Guo, Chunhua Bei, Huixia Zhang, Di Li, Xiaonian Zhu, Hongzhuan Tan
BMC Cancer.2022;[Epub]     CrossRef
PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity
Shuang Guo, Xinyue Wang, Hanxiao Zhou, Yue Gao, Peng Wang, Hui Zhi, Yue Sun, Yakun Zhang, Jing Gan, Yun Xiao, Shangwei Ning
Biomolecules.2022; 12(9): 1226.     CrossRef
The Clinicopathological Significance and Prognostic Value of PD-L2 in Patients with HCC, ICC and PAAD: A Meta-Analysis
Meng Gao, Yonghua Guo, Jinghua Li, Xi Chen, Yufeng Yuan, Weijie Ma
International Journal of Surgery: Oncology.2022; 7(1): 81.     CrossRef
Immunohistochemical expression of immune check point protein PDL-1 in hepatocellular carcinoma denotes its prognostic significance and association with survival
Dina Omar Helmy, Fatma Khattab, Azza Elsayed Hegazy, Rania Mohamed Sabry
Journal of Immunoassay and Immunochemistry.2022; : 1.     CrossRef
Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells
Enrico Munari, Linda Quatrini, Cecilia Ciancaglini, Albino Eccher, Giuseppe Bogina, Lorenzo Moretta, Francesca Romana Mariotti
Seminars in Immunology.2022; 61-64: 101660.     CrossRef
A retrospective study of PD-L1 immunohistochemistry for hepatocellular carcinoma
Min Du, Yumeng Cai, Yanrui Pang, Yuan Ji
iLIVER.2022; 1(3): 187.     CrossRef
Highlighting novel targets in immunotherapy for liver cancer
Samantha M. Ruff, Alexander H. Shannon, Joal D. Beane, Timothy M. Pawlik
Expert Review of Gastroenterology & Hepatology.2022; : 1.     CrossRef
Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma
Fei Fan, Keji Chen, Xiaoliang Lu, Aijun Li, Caifeng Liu, Bin Wu
Hepatology International.2021; 15(2): 444.     CrossRef
High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence
Ryo Muranushi, Kenichiro Araki, Takehiko Yokobori, Batbayar Chingunjav, Kouki Hoshino, Gantumur Dolgormaa, Kei Hagiwara, Takahiro Yamanaka, Norihiro Ishii, Mariko Tsukagoshi, Takamichi Igarashi, Akira Watanabe, Norio Kubo, Norifumi Harimoto, Yuki Shimoda,
Cancer Science.2021; 112(8): 3314.     CrossRef
Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers
Qingzhu Liu, Lei Jiang, Ke Li, Hang Li, Gaochao Lv, Jianguo Lin, Ling Qiu
Cancer Immunology, Immunotherapy.2021; 70(6): 1721.     CrossRef
ANO9 regulates PD‐L2 expression and binding ability to PD‐1 in gastric cancer
Keita Katsurahara, Atsushi Shiozaki, Toshiyuki Kosuga, Hiroki Shimizu, Michihiro Kudou, Tomohiro Arita, Hirotaka Konishi, Shuhei Komatsu, Takeshi Kubota, Hitoshi Fujiwara, Kazuma Okamoto, Mitsuo Kishimoto, Eiichi Konishi, Eigo Otsuji
Cancer Science.2021; 112(3): 1026.     CrossRef
Association between PD-L1 expression and 18F-FDG uptake in ovarian cancer
Yun Jung Choi, KwanHyeong Jo, Sang Hyun Hwang, YongHyu Jeong, Jung-Yun Lee, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Won Jun Kang
Annals of Nuclear Medicine.2021; 35(4): 415.     CrossRef
Association of TNIP1 polymorphisms with hepatocellular carcinoma in a Northwest Chinese Han population
Yuting Shi, Lihua Zhang, Yang Bao, Pengfei Wu, Xiaoli Zhang
Medicine.2021; 100(12): e24843.     CrossRef
PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
Yu Zhang, Guang-Ze Mou, Tian-Zhu Li, Wan-Ting Xu, Tong Zhang, Hui Xue, Wen-Bo Zuo, Yan-Nan Li, Ying-Hua Luo, Cheng-Hao Jin
Technology in Cancer Research & Treatment.2021; 20: 153303382110049.     CrossRef
High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition
Nishant Thakur, Kwang Yeol Paik, Gyoyeon Hwang, Yosep Chong
Diagnostics.2021; 11(4): 597.     CrossRef
ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma
Albert Chan, Wei Yi Zhang, Kenneth Chok, Jeff Dai, Ren Ji, Crystal Kwan, Nancy Man, Ronnie Poon, Chung Mau Lo
Annals of Surgery.2021; 273(5): 957.     CrossRef
Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins: Clinical and Molecular Implications in Hepatocellular Carcinoma
Yueh-Te Lin, Long-Bin Jeng, Wen-Ling Chan, Ih-Jen Su, Chiao-Fang Teng
Viruses.2021; 13(5): 862.     CrossRef
The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
Patrizia Leone, Antonio Giovanni Solimando, Rossella Fasano, Antonella Argentiero, Eleonora Malerba, Alessio Buonavoglia, Luigi Giovanni Lupo, Valli De Re, Nicola Silvestris, Vito Racanelli
Vaccines.2021; 9(5): 532.     CrossRef
Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?
Alice Boilève, Marc Hilmi, Matthieu Delaye, Annemilaï Tijeras-Raballand, Cindy Neuzillet
Cancers.2021; 13(11): 2708.     CrossRef
Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma
Qianhui Gu, Jing Li, Zhuolin Chen, Jie Zhang, Hui Shen, Xiaobing Miao, Ying Zhou, Xiaohong Xu, Song He
Frontiers in Oncology.2021;[Epub]     CrossRef
Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
Caecilia H C Sukowati, Korri Elvanita El-Khobar, Claudio Tiribelli
World Journal of Stem Cells.2021; 13(7): 795.     CrossRef
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
Alessandro Di Federico, Andrea De Giglio, Claudia Parisi, Francesco Gelsomino, Luca Boni, Andrea Ardizzoni
JTO Clinical and Research Reports.2021; 2(9): 100214.     CrossRef
Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment
Min Luo, Yan Lin, Rong Liang, Yongqiang Li, Lianying Ge
Journal of Inflammation Research.2021; Volume 14: 4217.     CrossRef
Tumor Mutation Burden-Associated LINC00638/miR-4732-3p/ULBP1 Axis Promotes Immune Escape via PD-L1 in Hepatocellular Carcinoma
Feng Qi, Xiaojing Du, Zhiying Zhao, Ding Zhang, Mengli Huang, Yuezong Bai, Biwei Yang, Wenxing Qin, Jinglin Xia
Frontiers in Oncology.2021;[Epub]     CrossRef
Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model
Shahrokh Abdolahi, Zeinab Ghazvinian, Samad Muhammadnejad, Mohammad Ahmadvand, Hamid Asadzadeh Aghdaei, Somayeh Ebrahimi-Barough, Jafar Ai, Mohammad Reza Zali, Javad Verdi, Kaveh Baghaei
Frontiers in Pharmacology.2021;[Epub]     CrossRef
Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy
Rossella Fasano, Mahdi Abdoli Shadbad, Oronzo Brunetti, Antonella Argentiero, Angela Calabrese, Patrizia Nardulli, Roberto Calbi, Behzad Baradaran, Nicola Silvestris
Life.2021; 11(12): 1355.     CrossRef
An RNA–RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity
Yanping Wei, Xuewu Tang, Yibin Ren, Yun Yang, Fengliang Song, Jingbo Fu, Shuowu Liu, Miao Yu, Jing Chen, Suyang Wang, Kecheng Zhang, Yexiong Tan, Zhipeng Han, Lixin Wei, Baohua Zhang, Zhangjun Cheng, Liang Li, Hongyang Wang
Signal Transduction and Targeted Therapy.2021;[Epub]     CrossRef
Identification and Validation of a Prognostic Prediction Model of m6A Regulator-Related LncRNAs in Hepatocellular Carcinoma
Chen Jin, Rui Li, Tuo Deng, Jialiang Li, Yan Yang, Haoqi Li, Kaiyu Chen, Huihua Xiong, Gang Chen, Yi Wang
Frontiers in Molecular Biosciences.2021;[Epub]     CrossRef
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
Huang Ao, Zhang Xin, Zhou Jian
Biomarker Research.2021;[Epub]     CrossRef
Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
Vishakha Singh, Amit Khurana, Prince Allawadhi, Anil Kumar Banothu, Kala Kumar Bharani, Ralf Weiskirchen
Frontiers in Pharmacology.2021;[Epub]     CrossRef
HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis
Cheng Zeng, Shaojun Ye, Yu Chen, Qu Zhang, Yan Luo, Liang Gai, Bo Luo, Xiao-Jie Lu
Journal of Immunology Research.2021; 2021: 1.     CrossRef
Construction and validation of an N6‑methyladenosine‑associated prognostic signature in hepatocellular carcinoma
Peng Zhu, Qianqian Ren, Nan He, Cheng Zhou, Qianna Jin, Zhao Gong
Oncology Letters.2021;[Epub]     CrossRef
Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?
Hye Won Lee, Kyung Joo Cho, Jun Yong Park
Immune Network.2020;[Epub]     CrossRef
Developments in predictive biomarkers for hepatocellular carcinoma therapy
Andrea Casadei-Gardini, Orsi Giulia, Caputo Francesco, Ercolani Giorgio
Expert Review of Anticancer Therapy.2020; 20(1): 63.     CrossRef
Immune-based therapies for hepatocellular carcinoma
David J. Pinato, Nadia Guerra, Petros Fessas, Ravindhi Murphy, Takashi Mineo, Francesco A. Mauri, Sujit K. Mukherjee, Mark Thursz, Ching Ngar Wong, Rohini Sharma, Lorenza Rimassa
Oncogene.2020; 39(18): 3620.     CrossRef
Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
Xiao-Song Li, Jun-Wei Li, Hui Li, Tao Jiang
Bioscience Reports.2020;[Epub]     CrossRef
Polymorphisms in Interleukin 13 Signaling and Interacting Genes Predict Advanced Fibrosis and Hepatocellular Carcinoma Development in Non-Alcoholic Steatohepatitis
Marwa O. El-Derany
Biology.2020; 9(4): 75.     CrossRef
PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions
Yu Toda, Kenichi Kohashi, Yuichi Yamada, Masato Yoshimoto, Shin Ishihara, Yoshihiro Ito, Takeshi Iwasaki, Hidetaka Yamamoto, Yoshihiro Matsumoto, Yasuharu Nakashima, Masaaki Mawatari, Yoshinao Oda
Journal of Cancer Research and Clinical Oncology.2020; 146(10): 2607.     CrossRef
The roles of programmed death ligand 1 in virus-associated cancers
Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki, Ebrahim Faghihloo
Infection, Genetics and Evolution.2020; 84: 104368.     CrossRef
Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis
Jinlan Piao, Hyun Ji Lim, Maria Lee
Obstetrics & Gynecology Science.2020; 63(3): 346.     CrossRef
Downexpression of HSD17B6 correlates with clinical prognosis and tumor immune infiltrates in hepatocellular carcinoma
Lei Lv, Yujia Zhao, Qinqin Wei, Ye Zhao, Qiyi Yi
Cancer Cell International.2020;[Epub]     CrossRef
Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer
Heejae Lee, Young-Ae Kim, Youngho Kim, Hye Seon Park, Jeong-Han Seo, Hyun Lee, Gyungyub Gong, Hee Jin Lee
Cancer Immunology, Immunotherapy.2020; 69(11): 2381.     CrossRef
TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma
Ritu Shrestha, Kim Bridle, Darrell Crawford, Aparna Jayachandran
Molecular Medicine Reports.2020;[Epub]     CrossRef
Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines
Qian Qian, Changping Wu, Jianping Chen, Weibing Wang
BioMed Research International.2020; 2020: 1.     CrossRef
Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden
Annie He Ren, Ioannis Prassas, Antoninus Soosaipillai, Stephanie Jarvi, Steven Gallinger, Vathany Kulasingam, Eleftherios P. Diamandis
F1000Research.2020; 9: 732.     CrossRef
Integrative bioinformatics analysis of a prognostic index and immunotherapeutic targets in renal cell carcinoma
Hongmiao Tao, Zeyu Li, Yuan Mei, Xiaoling Li, Hongqiang Lou, Lihua Dong, Liangcheng Zhou
International Immunopharmacology.2020; 87: 106832.     CrossRef

Development and Validation of a Novel 8 Immune Gene Prognostic Signature Based on the Immune Expression Profile for Hepatocellular Carcinoma

Dafeng Xu, Yu Wang, Kailun Zhou, Jincai Wu, Zhensheng Zhang, Jiachao Zhang, Zhiwei Yu, Luzheng Liu, Xiangmei Liu, Bidan Li, Jinfang Zheng
OncoTargets and Therapy.2020; Volume 13: 8125.     CrossRef
New landscapes and horizons in hepatocellular carcinoma therapy
Melchiorre Cervello, Maria R. Emma, Giuseppa Augello, Antonella Cusimano, Lydia Giannitrapani, Maurizio Soresi, Shaw M. Akula, Stephen L. Abrams, Linda S. Steelman, Alessandro Gulino, Beatrice Belmonte, Giuseppe Montalto, James A. McCubrey
Aging.2020; 12(3): 3053.     CrossRef
Immuno-oncology for Hepatocellular Carcinoma
Samantha A. Armstrong, Aiwu Ruth He
Clinics in Liver Disease.2020; 24(4): 739.     CrossRef
Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis
Xiaochun Lin, Kunpeng Lin, Chunxuan Lin, Jiakang Wang, Yunqiang Tang
International Immunopharmacology.2020; 88: 106946.     CrossRef
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update
Christo Kole, Nikolaos Charalampakis, Sergios Tsakatikas, Michail Vailas, Dimitrios Moris, Efthymios Gkotsis, Stylianos Kykalos, Michalis V. Karamouzis, Dimitrios Schizas
Cancers.2020; 12(10): 2859.     CrossRef
Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations
Qi Zhang, Yiwen Chen, Xueli Bai, Tingbo Liang
Frontiers in Oncology.2020;[Epub]     CrossRef
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
Piera Federico, Angelica Petrillo, Pasqualina Giordano, Davide Bosso, Antonietta Fabbrocini, Margaret Ottaviano, Mario Rosanova, Antonia Silvestri, Andrea Tufo, Antonio Cozzolino, Bruno Daniele
Cancers.2020; 12(10): 3025.     CrossRef
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, Yu Tian, Chaoliu Dai, Crystal Widarma, Rui Song, Feng Xu
Signal Transduction and Targeted Therapy.2020;[Epub]     CrossRef
Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
Yanjie Zhao, Feng Shi, Quan Zhou, Yuchen Li, Jiangping Wu, Ruibin Wang, Qingkun Song
Medicine.2020; 99(45): e23172.     CrossRef
Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma
Qiu-Ju Sheng, Wen-Yue Tian, Xiao-Guang Dou, Chong Zhang, Yan-Wei Li, Chao Han, Yao-Xin Fan, Ping-Ping Lai, Yang Ding
World Journal of Gastrointestinal Oncology.2020; 12(11): 1255.     CrossRef
Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden
Annie He Ren, Ioannis Prassas, Antoninus Soosaipillai, Stephanie Jarvi, Steven Gallinger, Vathany Kulasingam, Eleftherios P. Diamandis
F1000Research.2020; 9: 732.     CrossRef
Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers
Qijie Zhao, Jinan Guo, Yueshui Zhao, Jing Shen, Parham Jabbarzadeh Kaboli, Shixin Xiang, Fukuan Du, Xu Wu, Mingxing Li, Lin Wan, Xiang Li, Qinglian Wen, Jing Li, Chang Zou, Zhangang Xiao
Epigenomics.2020;[Epub]     CrossRef
PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer
Xiao-Li Wei, Xuan Luo, Hui Sheng, Yun Wang, Dong-Liang Chen, Jia-Ning Li, Feng-Hua Wang, Rui-Hua Xu
Journal of Translational Medicine.2020;[Epub]     CrossRef
PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
Lingyu Tian, Jiaqiang Ma, Lijie Ma, Bohao Zheng, Longzi Liu, Danjun Song, Yining Wang, Zhao Zhang, Qiang Gao, Kang Song, Xiaoying Wang
World Journal of Surgical Oncology.2020;[Epub]     CrossRef

Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant

Chiao-Fang Teng, Tsai-Chung Li, Ting Wang, Tzu-Hua Wu, John Wang, Han-Chieh Wu, Woei-Cherng Shyu, Ih-Jen Su, Long-Bin Jeng
Journal of Hepatocellular Carcinoma.2020; Volume 7: 385.     CrossRef
Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma
Bryan Mckiver, Mohamad Imad Damaj, Devanand Sarkar
Gastrointestinal Disorders.2020; 2(4): 469.     CrossRef
Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1
Naoshi Nishida, Kazuko Sakai, Masahiro Morita, Tomoko Aoki, Masahiro Takita, Satoru Hagiwara, Yoriaki Komeda, Mamoru Takenaka, Yasunori Minami, Hiroshi Ida, Kazuomi Ueshima, Kazuto Nishio, Masatoshi Kudo
Liver Cancer.2020; 9(4): 426.     CrossRef
Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
Amblessed E. Onuma, Hongji Zhang, Hai Huang, Terence M. Williams, Anne Noonan, Allan Tsung
Gene Expression.2020; 20(1): 53.     CrossRef
Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma
Xue Han, Yang-kui Gu, Shao-long Li, Hao Chen, Min-shan Chen, Qing-qing Cai, Han-xia Deng, Meng-xuan Zuo, Jin-hua Huang
Journal of Cancer Research and Clinical Oncology.2019; 145(2): 303.     CrossRef
Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
T. Mocan, Z. Sparchez, R. Craciun, C. N. Bora, D. C. Leucuta
Clinical and Translational Oncology.2019; 21(6): 702.     CrossRef
Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile
Manuel Weber, Falk Wehrhan, Christoph Baran, Abbas Agaimy, Maike Büttner‐Herold, Marco Kesting, Jutta Ries
Cancer Medicine.2019; 8(3): 1124.     CrossRef
Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis
Gao-Min Liu, Xu-Gang Li, Yao-Min Zhang
Cancer Cell International.2019;[Epub]     CrossRef
Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas
Takafumi Nakano, Katsumi Takizawa, Azusa Uezato, Kenichi Taguchi, Satoshi Toh, Muneyuki Masuda
Oral Oncology.2019; 90: 30.     CrossRef
Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma
Christian Ihling, Bartholomew Naughton, Yue Zhang, P. Alexander Rolfe, Eveline Frick-Krieger, Luigi M. Terracciano, Isabelle Dussault
Frontiers in Medicine.2019;[Epub]     CrossRef
Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis
Huayu Yang, Xiaoxiang Zhou, Lejia Sun, Yilei Mao
Frontiers in Oncology.2019;[Epub]     CrossRef
Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?
Jared H. Gans, Jeffrey Lipman, Yosef Golowa, Milan Kinkhabwala, Andreas Kaubisch
Seminars in Nuclear Medicine.2019; 49(3): 170.     CrossRef
Clinicopathological, immune and molecular correlates of PD-L2 methylation in gastric adenocarcinomas
Philipp Lingohr, Jonas Dohmen, Alexander Semaan, Vittorio Branchi, Jörn Dietrich, Friedrich Bootz, Jörg C Kalff, Hanno Matthaei, Dimo Dietrich
Epigenomics.2019; 11(6): 639.     CrossRef
Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors
Yutaka Fujiwara, Haruo Iguchi, Noboru Yamamoto, Manabu Hayama, Masahiro Nii, Shinya Ueda, Keiko Komuro, Mariko Sugimoto, Gordana Vlahovic, Toshiyuki Kozuki
Cancer Science.2019; 110(5): 1715.     CrossRef
Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study
Lin Wang
Journal of Ovarian Research.2019;[Epub]     CrossRef
Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges
Lifeng Wang, Fu-Sheng Wang
Hepatology International.2019; 13(5): 521.     CrossRef
Histology of Hepatocellular Carcinoma: Association with Clinical Features, Radiological Findings, and Locoregional Therapy Outcomes
Benjamin V. Park, Ron C. Gaba, Yu-Hui Huang, Yi-Fan Chen, Grace Guzman, R. Peter Lokken
Journal of Clinical Imaging Science.2019; 9: 52.     CrossRef
Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
De Re, Caggiari, Repetto, Mussolin, Mascarin
Journal of Clinical Medicine.2019; 8(10): 1596.     CrossRef
A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma
Yiyin Zhang, Jin Xu, Jie Hua, Jiang Liu, Chen Liang, Qingcai Meng, Miaoyan Wei, Bo Zhang, Xianjun Yu, Si Shi
Journal for ImmunoTherapy of Cancer.2019;[Epub]     CrossRef
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
Zuzana Macek Jilkova, Caroline Aspord, Thomas Decaens
Cancers.2019; 11(10): 1554.     CrossRef
Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma
Hye Won Lee, Kyung Joo Cho, Soon Young Shin, Ha Yan Kim, Eun Ju Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han
Journal of Liver Cancer.2019; 19(2): 108.     CrossRef
Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
Haotian Liao, Wen Chen, Yunlu Dai, Joseph J. Richardson, Junling Guo, Kefei Yuan, Yong Zeng, Kunlin Xie
Frontiers in Oncology.2019;[Epub]     CrossRef
Significance of PD‑L1 clones and C‑MET expression in hepatocellular carcinoma
Hyung‑Wook Chun, Ran Hong
Oncology Letters.2019;[Epub]     CrossRef
Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade
Hong Jae Chon, Won Suk Lee, Hannah Yang, So Jung Kong, Na Keum Lee, Eun Sang Moon, Jiwon Choi, Eun Chun Han, Joo Hoon Kim, Joong Bae Ahn, Joo Hang Kim, Chan Kim
Clinical Cancer Research.2019; 25(5): 1612.     CrossRef
Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database
Neil Mehta, Jennifer L. Dodge, John P. Roberts, Francis Y. Yao
American Journal of Transplantation.2018; 18(5): 1206.     CrossRef
Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers
Belinda Lee, Ryan Hutchinson, Hui-Li Wong, Jeanne Tie, Tracy Putoczki, Ben Tran, Peter Gibbs, Michael Christie
Seminars in Cancer Biology.2018; 52: 241.     CrossRef
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
Dagmar Kollmann, Desislava Ignatova, Julia Jedamzik, Yun-Tsan Chang, Gerd Jomrich, Andreas Baierl, Dmitry Kazakov, Michal Michal, Lars E. French, Wolfram Hoetzenecker, Tobias Schatton, Reza Asari, Matthias Preusser, Michael Gnant, Emmanuella Guenova, Seba
OncoImmunology.2018;[Epub]     CrossRef
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
Bingxin Zheng, Tingting Ren, Yi Huang, Kunkun Sun, Shidong Wang, Xing Bao, Kuisheng Liu, Wei Guo
Journal of Hematology & Oncology.2018;[Epub]     CrossRef
Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab
Yoshihiro Nozawa, Yuka Oka, Jun Oosugi, Shinichi Takemura
Medicine.2018; 97(19): e0718.     CrossRef
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Ioannis Zerdes, Alexios Matikas, Jonas Bergh, George Z. Rassidakis, Theodoros Foukakis
Oncogene.2018; 37(34): 4639.     CrossRef
Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
Jing-Hua Li, Wei-Jie Ma, Gang-Gang Wang, Xiang Jiang, Xi Chen, Long Wu, Zhi-Su Liu, Xian-Tao Zeng, Fu-Ling Zhou, Yu-Feng Yuan
Frontiers in Immunology.2018;[Epub]     CrossRef
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity
Alisa B. Lee-Sherick, Kristen M. Jacobsen, Curtis J. Henry, Madeline G. Huey, Rebecca E. Parker, Lauren S. Page, Amanda A. Hill, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Craig T. Jordan, Deborah DeRyckere, Douglas K. Graham
JCI Insight.2018;[Epub]     CrossRef
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
Jaafar Jaafar, Eugenio Fernandez, Heba Alwan, Jacques Philippe
Endocrine Connections.2018; 7(5): R196.     CrossRef
Prognostic value of PD -L1 expression in patients with primary solid tumors
Xiao Xiang, Peng-Cheng Yu, Di Long, Xiao-Li Liao, Sen Zhang, Xue-Mei You, Jian-Hong Zhong, Le-Qun Li
Oncotarget.2018; 9(4): 5058.     CrossRef
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia
Alexander Semaan, Dimo Dietrich, Dominik Bergheim, Jörn Dietrich, Jörg C. Kalff, Vittorio Branchi, Hanno Matthaei, Glen Kristiansen, Hans-Peter Fischer, Diane Goltz
Virchows Archiv.2017; 470(2): 185.     CrossRef
Soluble PD-L1 and prognosis of patients with hepatocellular carcinoma
Cheng-Piao Luo, Han-Yue Mo, Ling-Ling Wu, Yun Ma, Ning-Fu Peng
European Journal of Cancer.2017; 71: 117.     CrossRef
Immune checkpoints and their inhibition in cancer and infectious diseases
Lydia Dyck, Kingston H.G. Mills
European Journal of Immunology.2017; 47(5): 765.     CrossRef
Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma
Hyeyoon Chang, Wonkyung Jung, Aeree Kim, Han Kyeom Kim, Wan Bae Kim, Ji Hoon Kim, Baek-hui Kim
APMIS.2017; 125(8): 690.     CrossRef
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
Junyu Long, Jianzhen Lin, Anqiang Wang, Liangcai Wu, Yongchang Zheng, Xiaobo Yang, Xueshuai Wan, Haifeng Xu, Shuguang Chen, Haitao Zhao
Journal of Hematology & Oncology.2017;[Epub]     CrossRef
PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer
Dagmar Kollmann, Thomas Schweiger, Stefan Schwarz, Desislava Ignatova, Yun-Tsan Chang, Gerrit Lewik, Sebastian F. Schoppmann, Wolfram Hoetzenecker, Walter Klepetko, Emmanuella Guenova, Konrad Hoetzenecker
OncoImmunology.2017; 6(9): e1331194.     CrossRef
PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer
Yanhua Wu, Donghui Cao, Limei Qu, Xueyuan Cao, Zhifang Jia, Tiancheng Zhao, Quan Wang, Jing Jiang
Oncotarget.2017; 8(38): 64066.     CrossRef